This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third Look: Delving into the recent topline data from the FIBRONEER-IPF clinical trial of nerandomilast in patients with IPF
Ticker(s): BOEHRINGER INGELHEIMWho's the expert?
Shirish Amrutia, MD
- specializes in COPD, asthma, pulmonary nodules and cancers, obstructive and central sleep apneas, complex sleep-disordered breathing, narcolepsy, restless leg syndrome, circadian rhythm disorders and insomnia.
- 250 COPD patients annually approximately
- Yes familiar with ENHANCE and Ensifentrine, eagerly waiting for FDA approval in near future
Interview Goalto discuss the current treatment landscape and the potential of nerandomilast a therapy being developed by Boehringer Ingelheim for the treatment of interstitial lung diseases.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
